• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by FMC Corporation

    2/4/26 5:23:07 PM ET
    $FMC
    Major Chemicals
    Industrials
    Get the next $FMC alert in real time by email
    S-8 1 dp241085_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 4, 2026 

    Registration No. 333-    

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    FMC Corporation
    (Exact name of Registrant as specified in its charter)

     

    Delaware   94-0479804
    (State or other jurisdiction of
    Incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    2929 Walnut Street
    Philadelphia, PA 19104
    Telephone: (215) 299-6000
    (Address of principal executive offices) (Zip code)

     

    FMC Corporation 2026 Incentive Stock Plan
    (Full title of the plan)

     

    Sara Ponessa, Executive Vice President, General Counsel and Corporate Secretary
    FMC Corporation
    2929 Walnut Street
    Philadelphia, Pennsylvania 19104
    (Name and address of agent for service)

     

    (215) 299-6000
    (Telephone number, including area code, of agent for service)

     

    With copies to:

     

    Jennifer S. Conway
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, New York 10017
    (212) 450-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☒ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☐
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (“Registration Statement”) is being filed by FMC Corporation (“Registrant”) for the purpose of registering 5,250,000 shares of the Registrant’s Common Stock, par value $0.10, that may become available for issuance under the FMC Corporation 2026 Incentive Stock Plan, which is subject to approval by the Registrant’s stockholders at the next annual general meeting of the Registrant’s stockholders.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information required by Part I of Form S-8 is omitted from this filing in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. The documents containing the information specified in Part I will be sent or given to the participant in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    (i)the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 28, 2025 (File No. 001-02376);

     

    (ii)the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 1, 2025 (File No. 001-02376);

     

    (iii)the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on July 31, 2025 (File No. 001-02376);

     

    (iv)the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on October 30, 2025 (File No. 001-02376);

     

    (v)all other reports filed by the Registrant pursuant to Section 13(a) or Section 15(d) of the Exchange Act, since December 31, 2024 (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on that form that relate to such items); and

     

    (vi)the description of the Registrant’s Capital Stock contained in Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all of the above-referenced descriptions included in any prospectus relating to the Registration Statement filed with the Commission pursuant to Rule 424(b) under the Securities Act shall be deemed to be incorporated by reference herein.

     

    All other reports and documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in the Registration Statement and to be part thereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant is organized under the laws of the State of Delaware. The General Corporation Law of the State of Delaware, as amended (the “DGCL”), provides that a Delaware corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director or officer of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expense, liability or loss (including attorneys’ fees, judgments, fines and amounts paid in settlement) reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. In the case of an action or suit brought by or in the right of the corporation, indemnification of any director, officer and other agent against expenses actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit is permitted if such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation; however, no indemnification is permitted in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Delaware Court of Chancery, or the court in which such action or suit was brought, shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper. Article XI of the Registrant’s Restated By-Laws provides for the indemnification of directors and officers of the Registrant each of whom was or is made a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “Proceeding”), by reason of the fact that he or she or a person of whom he or she is the legal representative is or was a director or officer of the Registrant or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans maintained or sponsored by the Registrant, whether the basis of such Proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, to the fullest extent permitted by the DGCL and specifies procedures to be followed by the Registrant and any person requesting indemnification in connection with any claim.

     

    Under the DGCL, a Delaware corporation has the power to purchase and maintain insurance on behalf of any director, officer, employee or other agent of the Registrant or, if serving in such capacity at the request of the Registrant, of another enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation has the power to indemnify such person against such liability under the DGCL. The Registrant has purchased directors and officers liability insurance. A Delaware corporation also may, with certain limitations, set forth in its certificate of incorporation a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of a fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (1) for any breach of the director’s duty of loyalty to the Registrant or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) under Section 174 of the DGCL (relating to unlawful payments of dividends or stock repurchases), or (4) for any transaction from which the director derived an improper personal benefit. Article Eighth of the Registrant’s Restated Certificate of Incorporation includes such a provision.

     

     

     

    Item 7. Exemption from Registration Counsel.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
    4.1   Restated Certificate of Incorporation, as amended through April 30, 2019, incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on May 8, 2019.
    4.2   Restated By-Laws of the Registrant as of December 14, 2022, incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on December 15, 2022.
    5.1*   Opinion of Davis Polk & Wardwell LLP
    23.1*   Consent of KPMG, Independent Registered Public Accounting Firm
    23.2*   Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
    24.1*   Power of Attorney (included on signature page)
    99.1*   FMC Corporation 2026 Incentive Stock Plan
    107.1*   Filing Fee Table

    *Filed herewith.

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

     

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on February 4, 2026.

     

      FMC CORPORATION
         
    Date: February 4, 2026 By: /s/ Pierre R. Brondeau
        Pierre R. Brondeau, Ph.D.
        Chairman, Chief Executive Officer and President

     

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Pierre R. Brondeau, Nicholas L. Pfeiffer and Andrew D. Sandifer, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Pierre R. Brondeau   Chairman, Chief Executive Officer and President (Principal Executive Officer)   February 4, 2026
    Pierre R. Brondeau, Ph.D.    
             
             
    /s/ Andrew Sandifer   Chief Financial Officer (Principal Financial
    Officer)
      February 4, 2026
    Andrew Sandifer    
             
             
    /s/ Nicholas L. Pfeiffer   Vice President, Corporate Controller and Chief Accounting Officer (Principal Accounting Officer)   February 4, 2026
    Nicholas L. Pfeiffer    
             
             
    /s/ Eduardo E. Cordeiro   Director   February 4, 2026
    Eduardo E. Cordeiro    
             
             
    /s/ Carol Anthony (“John”) Davidson   Director   February 4, 2026
    Carol Anthony (“John”) Davidson    
             
             
    /s/ Kathy L. Fortmann   Director   February 4, 2026
    Kathy L. Fortmann    
             
             
    /s/ C. Scott Greer   Director   February 4, 2026
    C. Scott Greer    
             
             
    /s/ K’Lynne Johnson   Director   February 4, 2026
    K’Lynne Johnson    
             
             
    /s/ Dirk A. Kempthorne   Director   February 4, 2026
    Dirk A. Kempthorne    
             
             
    /s/ Steven T. Merkt   Director   February 4, 2026
    Steven T. Merkt    
             
             
    /s/ Margareth Øvrum   Director   February 4, 2026
    Margareth Øvrum    
             
             
    /s/ Robert C. Pallash   Director   February 4, 2026
    Robert C. Pallash    
             
             
    /s/ John M. Raines   Director   February 4, 2026
    John M. Raines    
             
             
    /s/ Patricia Verduin   Director   February 4, 2026
    Patricia Verduin, Ph.D.    

     

     

    Get the next $FMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FMC

    DatePrice TargetRatingAnalyst
    12/9/2025$13.00Equal Weight → Underweight
    Barclays
    11/11/2025$16.00Equal Weight
    Wells Fargo
    10/31/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    10/31/2025$16.00Overweight → Equal Weight
    Wells Fargo
    10/30/2025$22.00Overweight → Equal Weight
    Barclays
    10/14/2025$33.00Underperform → Neutral
    BofA Securities
    6/23/2025$50.00Equal Weight → Overweight
    Wells Fargo
    4/25/2025$49.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $FMC
    SEC Filings

    View All

    SEC Form S-8 filed by FMC Corporation

    S-8 - FMC CORP (0000037785) (Filer)

    2/4/26 5:23:07 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - FMC CORP (0000037785) (Filer)

    2/4/26 5:05:56 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Material Impairments

    8-K - FMC CORP (0000037785) (Filer)

    12/12/25 4:14:41 PM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FMC Corporation sets 2026 priorities and announces exploration of strategic options including but not limited to the sale of the company

    Company reports 2025 fourth quarter and full year results, provides 2026 outlook  The organization continues to focus on its 2026 operational priorities, including strengthening the balance sheet, improving the competitiveness of its core portfolio, managing its post-patent Rynaxypyr® active strategy and supporting growth of new active ingredientsThe FMC Board of Directors has authorized the exploration of strategic options, including but not limited to, the sale of the company to unlock shareholder value and ensure its growth and core portfolios are best positioned for long-term success PHILADELPHIA, Feb. 4, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced its 2026 prioritie

    2/4/26 5:00:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation Announces Date of 2026 Annual Meeting of Stockholders

    PHILADELPHIA, Jan. 22, 2026 /PRNewswire/ -- FMC Corporation (NYSE:FMC) announced today that its 2026 Annual Meeting of Stockholders will be held via live webcast on Tuesday, April 28, 2026, at 2:00 p.m. ET. The board of directors established the close of business on Friday, February 27, 2026, as the record date for determining stockholders entitled to receive notice of and vote at the annual meeting. Further information regarding the annual meeting will be set forth in the proxy statement and other proxy materials. Instructions for accessing the webcast will be available on the company's Investor Relations website at https://investors.fmc.com. About FMC FMC Corporation is a global agricultu

    1/22/26 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation announces date for fourth quarter 2025 earnings release and webcast conference call

    PHILADELPHIA, Dec. 22, 2025 /PRNewswire/ -- FMC Corporation (NYSE:FMC) announced today it will release its fourth quarter 2025 earnings on Wednesday, February 4, 2026, after the stock market close via PR Newswire and the company's website https://investors.fmc.com. The company will host a webcast conference call on Thursday, February 5, 2026, at 9:00 a.m. ET that is open to the public via internet broadcast and telephone. Conference Call Details: Internet broadcast: https://investors.fmc.com United States (Local): +1 646 844 6383United States (Toll-Free): +1 833 470 1428Global Dial-In Numbers:  Global Dial-in NumberAccess Code: 827087 Pre-Registration Link: https://www.netroadshow.com/event

    12/22/25 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cordeiro Eduardo E was granted 88 shares, increasing direct ownership by 0.28% to 31,634 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    1/16/26 10:57:19 AM ET
    $FMC
    Major Chemicals
    Industrials

    Director Davidson Carol Anthony was granted 49 shares, increasing direct ownership by 0.21% to 23,276 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    1/16/26 10:56:11 AM ET
    $FMC
    Major Chemicals
    Industrials

    Director Fortmann Kathy Lynn was granted 63 shares, increasing direct ownership by 0.44% to 14,326 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    1/16/26 10:54:58 AM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FMC Corp downgraded by Barclays with a new price target

    Barclays downgraded FMC Corp from Equal Weight to Underweight and set a new price target of $13.00

    12/9/25 8:38:38 AM ET
    $FMC
    Major Chemicals
    Industrials

    Wells Fargo resumed coverage on FMC Corp with a new price target

    Wells Fargo resumed coverage of FMC Corp with a rating of Equal Weight and set a new price target of $16.00

    11/11/25 8:04:56 AM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corp downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded FMC Corp from Overweight to Sector Weight

    10/31/25 8:18:01 AM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Raines John Mitchell bought $96,390 worth of shares (7,000 units at $13.77), increasing direct ownership by 103% to 13,784 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    11/14/25 9:19:38 AM ET
    $FMC
    Major Chemicals
    Industrials

    Director Davidson Carol Anthony bought $135,957 worth of shares (10,000 units at $13.60), increasing direct ownership by 76% to 23,227 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    11/7/25 8:36:59 AM ET
    $FMC
    Major Chemicals
    Industrials

    Director Davidson Carol Anthony bought $223,987 worth of shares (6,000 units at $37.33) (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    3/6/25 12:07:01 PM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Leadership Updates

    Live Leadership Updates

    View All

    FMC Corporation sets 2026 priorities and announces exploration of strategic options including but not limited to the sale of the company

    Company reports 2025 fourth quarter and full year results, provides 2026 outlook  The organization continues to focus on its 2026 operational priorities, including strengthening the balance sheet, improving the competitiveness of its core portfolio, managing its post-patent Rynaxypyr® active strategy and supporting growth of new active ingredientsThe FMC Board of Directors has authorized the exploration of strategic options, including but not limited to, the sale of the company to unlock shareholder value and ensure its growth and core portfolios are best positioned for long-term success PHILADELPHIA, Feb. 4, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced its 2026 prioritie

    2/4/26 5:00:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation Reports Third Quarter Results

    Company reports Adjusted EBITDA and Adjusted EPS above guidance midpoints despite lower-than-expected sales Third Quarter 2025 Highlights Revenue of $542 million, down 49 percent versus Q3 2024, impacted by significant one-time commercial actions taken in India to position the business for saleRevenue excluding India of $961 million, down 10 percent versus Q3 2024 (which included India); organic revenue for the period declined 11 percentConsolidated GAAP net loss of $569 million, a decline of $634 million versus Q3 2024, mainly driven by India charges and write-downAdjusted EBITDA of $236 million, up 17 percent versus Q3 2024 (which included India)Consolidated GAAP net loss of $4.52 per dilu

    10/29/25 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation Reports Second Quarter Results at High End of Guidance Range

    Maintains full year adjusted EBITDA and adjusted EPS guidance; announces sale of India commercial business Second Quarter 2025 Highlights Revenue of $1.05 billion, up 1 percent versus Q2 2024, up 2 percent organically1 Consolidated GAAP net income of $67 million, a decline of 77 percent versus Q2 2024Adjusted EBITDA of $207 million, up 2 percent versus Q2 2024Consolidated GAAP net income of $0.53 per diluted share, down 77 percent versus Q2 2024Adjusted earnings per diluted share of $0.69, an increase of 10 percent versus Q2 2024Full-Year Outlook2 Revenue outlook of $4.08 billion to $4.28 billion, excluding India, down 2 percent at the midpoint versus 2024 reported results, which included I

    7/30/25 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Financials

    Live finance-specific insights

    View All

    FMC Corporation Announces Date of 2026 Annual Meeting of Stockholders

    PHILADELPHIA, Jan. 22, 2026 /PRNewswire/ -- FMC Corporation (NYSE:FMC) announced today that its 2026 Annual Meeting of Stockholders will be held via live webcast on Tuesday, April 28, 2026, at 2:00 p.m. ET. The board of directors established the close of business on Friday, February 27, 2026, as the record date for determining stockholders entitled to receive notice of and vote at the annual meeting. Further information regarding the annual meeting will be set forth in the proxy statement and other proxy materials. Instructions for accessing the webcast will be available on the company's Investor Relations website at https://investors.fmc.com. About FMC FMC Corporation is a global agricultu

    1/22/26 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation announces date for fourth quarter 2025 earnings release and webcast conference call

    PHILADELPHIA, Dec. 22, 2025 /PRNewswire/ -- FMC Corporation (NYSE:FMC) announced today it will release its fourth quarter 2025 earnings on Wednesday, February 4, 2026, after the stock market close via PR Newswire and the company's website https://investors.fmc.com. The company will host a webcast conference call on Thursday, February 5, 2026, at 9:00 a.m. ET that is open to the public via internet broadcast and telephone. Conference Call Details: Internet broadcast: https://investors.fmc.com United States (Local): +1 646 844 6383United States (Toll-Free): +1 833 470 1428Global Dial-In Numbers:  Global Dial-in NumberAccess Code: 827087 Pre-Registration Link: https://www.netroadshow.com/event

    12/22/25 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation Declares Quarterly Dividend

    PHILADELPHIA, Dec. 12, 2025 /PRNewswire/ -- FMC Corporation (NYSE:FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on January 15, 2026, to shareholders of record as of the close of business on December 31, 2025. About FMC FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while pr

    12/12/25 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    $FMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FMC Corporation

    SC 13G/A - FMC CORP (0000037785) (Subject)

    11/8/24 10:46:38 AM ET
    $FMC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by FMC Corporation (Amendment)

    SC 13G/A - FMC CORP (0000037785) (Subject)

    2/13/24 5:04:36 PM ET
    $FMC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by FMC Corporation (Amendment)

    SC 13G/A - FMC CORP (0000037785) (Subject)

    1/10/24 9:08:13 AM ET
    $FMC
    Major Chemicals
    Industrials